REPEAT-PAH: Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH
Study Details
Study Description
Brief Summary
The purpose of this study is to examine N-terminal pro brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) biomarkers in a number of different settings including assessing the repeatability of laboratory and point of care testing (POCT), the effect of a time delay and exercise have on laboratory measurements. Also to compare the clinical and analytical performances of NT-proBNP and BNP POCT samples across the spectrum of disease severity and finally assess whether POCT in PAH can detect change in patients commencing or escalating PAH treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
-
Patients that are attending clinical appointments will be approached to ask if they will take part in the study.
-
Patients will be assessed at two separate visits.
-
Patients will be randomised to either exercise or rest group on their 1st visit. On the 2nd visit patients will be asked to participate in the alternate group to what they completed on their previous visit.
-
At each visit they will have 2 blood samples taken, at time point 1 and at time point 2 (T1 and T2). These will be taken at least one hour apart, each with a period of at least 15 mins rest in the sitting position prior to sampling.
-
On one of these two visits the patient will undergo exercise testing between T1 and T2.
-
In addition, a further laboratory testing tube will be taken for a delayed NT-proBNP. This will be subjected to gentle agitation (laboratory rotator) for 48 hours prior to processing to simulate, in a controlled environment, the effect of transport and delay on sample measurement.
-
Retrospectively information will be collected regarding the patient's disease severity and any change to treatment that occurred between the two visits.
-
A total of 40 patients with be sampled with an interim analysis after 20 patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Exercise Patients who have been randomised to the exercise group will be asked to undertake a incremental shuttle walking test following their initial blood tests. |
Other: Exercise group
Incremental Shuttle Walking Test
|
| No Exercise Patients who have been randomised to the exercise group will be asked to rest for 60 minutes following their initial blood tests. |
Outcome Measures
Primary Outcome Measures
- The repeatability of laboratory and POCT samples for NT-proBNP and BNP in patients at rest with PAH. [18 months]
Comparisons will be made between time point 1 (T1) and 2 (T2) in the absence of exercise for venous blood using POCT kits and for venous blood using laboratory analysis, for both BNP and NT-proBNP.
- The effect of a pre-processing time delay on performance of NT-proBNP test [18 months]
Comparison will be made between samples sent directly to the laboratory and those that were delayed in being sent by 48 hours. Pre-specified levels will be used to determine the performance of the test as excellent (eg >=0.75), good, fair or poor.
- The impact of exercise testing using the incremental shuttle walking test (ISWT) on NT-proBNP and BNP on both laboratory and POCT samples [18 months]
Comparison will be made between venous blood using POCT kits and venous blood using laboratory testing at rest and post exercise, for both BNP and NT-proBNP.
- The impact of treatment change or escalation on the results of POCT and The change in POCT and laboratory samples for NT-proBNP and BNP. [18 months]
POCT and laboratory samples for NT-proBNP and BNP will be assessed to see if they detected change in patients who had a change or escalation in treatment.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients who have met the criteria for The Sheffield Teaching Hospitals Observational Study of Patients with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-ObS)
-
Patient diagnosed with Group 1 PAH, including IPAH, HPAH, PAH-CTD but excluding PAH-CHD. Mean pulmonary artery pressure >20mmHg, PAWP ≤15mmHg and PVR >240 dynes.
-
Willing to participate in the study and able to provide informed consent
Exclusion Criteria:
-
Diagnosed with PAH-CHD or any non-group 1 PH
-
Creatinine clearance < 15 ml/min/m2
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital | Sheffield | South Yorkshire | United Kingdom | S10 2JF |
Sponsors and Collaborators
- Sheffield Teaching Hospitals NHS Foundation Trust
- Actelion
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STH20981